BRAINTEASER project aims to support patients with amyotrophic lateral sclerosis and multiple sclerosis and their clinicians. “Amyotrophic Lateral Sclerosis” campaign wants to bring attention to this condition and analyse the variables that might affect its progression. In “The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis” M. Kelly et al. report the results of an exploratory, non-controlled, nondrug study that aimed to objectively monitor ALS patients at home, to explore novel disease progression markers.
[Get to Know more about Amyotrophic Lateral Sclerosis] The use of biotelemetry to explore disease
OUR NEWSLETTER
Latest posts
European Carers Day: An Opportunity to Show More Care to Those Who Provide Support
On 6 October 2022, we recognise European Carers Day, a campaign led by Eurocarers. It aims to...
BRAINTEASER Conference Paper on Design and Optimization of REST Service Layer presented at ICCE Berlin 2022
Vladimir Urosevic, Research and Development Manager of Belit, represented the BRAINTEASER...
An Interview with Nicola Ferro: Discovering The iDPP@CLEF Challenge 2022
BRAINTEASER is excited to take part in the iDPP@CLEF Challenge 2022 happening on 5-8 September, We...